AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
4min chapter
Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett
Touching Base
Introduction
Discussion of Intelliya's latest clinical trial using NTLA 2002, a gene therapy based on CRISPR-Cas9, which showed safety and effectiveness in reducing angioedema attacks. The therapy has gained priority status by the EMA and future studies are planned.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode